10 results found
Efferon, a Startup Battlefield 200 participant, is combating pediatric sepsis with Efferon NEO, a blood purification device. It reduces organ failure and accelerates recovery in children by uniquely absorbing both endotoxins and cytokines. Already CE-marked and used in 30 countries, Efferon is now seeking FDA approval, aiming to save millions of young lives.
Jean-Christophe Laloux, incoming EIF chief, announced that funds backed by the European Tech Champions Initiative now hold 15 unicorn companies. He detailed plans to expand the initiative to support smaller funds and attract co-investors, emphasizing the importance of scaling European startups within the continent for "sovereignty." The EIF will prioritize investments in deep tech, including AI, biotech, defense, and cleantech.
Biotech startup InduPro has secured $77 million in Series B funding and commenced its first human clinical trial for lead cancer drug IDP-001. The company's novel proximity-guided platform aims to precisely target tumors by identifying specific protein combinations on cancer cell surfaces, sparing healthy tissue. This milestone, alongside a significant Eli Lilly partnership, marks a pivotal step for the Seattle and Cambridge-based firm.
Quick Verdict Amidst a disturbing rise in US measles cases, biotech firms are stepping up to develop new treatments, offering a beacon of hope where medical options are currently severely limited. While the scientific
Eli Lilly is set to acquire Seattle-area biotech Curevo Vaccine for up to $1.5 billion to bolster its infectious disease portfolio. The deal centers on Curevo's Phase 3-ready shingles vaccine candidate, amezosvatein, which demonstrated a more than 50% reduction in side effects during Phase 2 studies, aiming to boost vaccination rates among older adults.
Colossal's artificial egg offers a revolutionary platform for observing avian embryo development and a crucial step for de-extinction, overcoming long-standing research challenges.
Mantis Biotech has secured $7.4 million in seed funding to advance its platform for creating 'digital twins' of humans. These physics-based, predictive models aim to solve the critical data availability issues in biomedical research, especially for rare diseases, by generating synthetic datasets. Currently, Mantis is applying its technology in professional sports to predict athlete performance and injury, with plans to expand into preventative healthcare and pharmaceutical research.
Europe's tech sector saw over $1.1 billion in funding and fund closes from March 23-29, with significant investments flowing into deep tech, AI infrastructure, and a diverse range of sectors including biotech, space, and defense. This highlights a strategic continental focus on foundational innovations and long-term technological advancements.
Utrecht, Netherlands – Laigo Bio, a pioneering Dutch biotech firm, has successfully concluded an oversubscribed €17 million seed funding round. The substantial capital infusion, which saw an additional €5.5 million
Billionaire-backed startup R3 Bio is developing genetically-engineered, nonsentient "organ sacks" to replace animal testing. This initiative aligns with the Trump administration's efforts to phase out animal experimentation, offering a potentially humane and effective alternative for scientific research. The company aims to eventually create human versions for personalized medical testing.
